Barton A. Kamen

Q: What Schools Are Affiliated With Barton A. Kamen

Barton A. Kamen is affiliated with the following schools: University of Medicine and Dentistry of New Jersey, University of Texas Southwestern Medical Center

Barton A. Kamen's AcademicInfluence.com Rankings

Barton A. Kamen

Philosophy

#8980

World Rank

#12469

Historical Rank

Logic

#5987

World Rank

#7457

Historical Rank

philosophy Degrees

Barton A. Kamen

Biology

#12270

World Rank

#15734

Historical Rank

Biochemistry

#2080

World Rank

#2224

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Why Is Barton A. Kamen Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Barton A. Kamen's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The anti-angiogenic basis of metronomic chemotherapy (2004) (1348)
Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. (1992) (1019)
Potocytosis: sequestration and transport of small molecules by caveolae. (1992) (740)
Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate (1990) (537)
The glycophospholipid-linked folate receptor internalizes folate without entering the clathrin-coated pit endocytic pathway (1990) (422)
Mice lacking the folic acid-binding protein Folbp1 are defective in early embryonic development (1999) (358)
Cellular localization of the folate receptor: potential role in drug toxicity and folate homeostasis. (1992) (335)
Receptor-mediated folate accumulation is regulated by the cellular folate content. (1986) (332)
Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. (1991) (303)
Delivery of folates to the cytoplasm of MA104 cells is mediated by a surface membrane receptor that recycles. (1988) (283)
Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. (1993) (257)
A review of folate receptor alpha cycling and 5-methyltetrahydrofolate accumulation with an emphasis on cell models in vitro. (2004) (247)
Lowering the cholesterol content of MA104 cells inhibits receptor- mediated transport of folate (1992) (233)
Complementary DNA for the folate binding protein correctly predicts anchoring to the membrane by glycosyl-phosphatidylinositol. (1989) (230)
Methotrexate metabolism analysis in blood and liver of rheumatoid arthritis patients. Association with hepatic folate deficiency and formation of polyglutamates. (1986) (215)
Folate and antifolate pharmacology. (1997) (192)
Protein kinase C activators inhibit receptor-mediated potocytosis by preventing internalization of caveolae (1994) (190)
Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. (2002) (188)
Elevation of homocysteine and excitatory amino acid neurotransmitters in the CSF of children who receive methotrexate for the treatment of cancer. (1997) (183)
Aminophylline for methotrexate-induced neurotoxicity (1995) (152)
Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate (2003) (143)
The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro. (1991) (125)
DEXTROMETHORPHAN IS EFFECTIVE IN THE TREATMENT OF SUBACUTE METHOTREXATE NEUROTOXICITY (2002) (115)
Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. (1984) (113)
Methotrexate Accumulation and Folate Depletion in Cells as a Possible Mechanism of Chronic Toxicity to the Drug (1981) (111)
High-time chemotherapy or high time for low dose. (2000) (105)
Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate. (1992) (101)
Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. (1992) (95)
The folate receptor in central nervous system malignancies of childhood (2005) (92)
Interaction of cisplatin and noise on the peripheral auditory system (1990) (92)
Characterization of folate uptake by choroid plexus epithelial cells in a rat primary culture model (2008) (91)
Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion. (1985) (84)
Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia. (2006) (81)
A rapid, radiochemical-ligand binding assay for methotrexate. (1976) (80)
Functional Folate Receptor Alpha Is Elevated in the Blood of Ovarian Cancer Patients (2009) (77)
Establishment of methotrexate-resistant human acute lymphoblastic leukemia cells in culture and effects of folate antagonists. (1982) (71)
A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. (1996) (68)
Evolution of methotrexate resistance of human acute lymphoblastic leukemia cells in vitro. (1985) (67)
Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies (2000) (61)
Properties of a folate binding protein (FBP) isolated from porcine kidney. (1986) (57)
Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology. (1997) (53)
Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate. (1989) (52)
Direct radiochemical assay for serum folate: competition between 3H-folic acid and 5-methyltetrahydrofolic acid for a folate binder. (1974) (52)
Regulation of the cytoplasmic accumulation of 5-methyltetrahydrofolate in MA104 cells is independent of folate receptor regulation. (1989) (51)
A Phase 1 Study of Nifurtimox in Patients With Relapsed/Refractory Neuroblastoma (2011) (49)
Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. (1996) (49)
Identification of a folate binder in hog kidney. (1975) (47)
Purification of folate binding factor in normal umbilical cord serum. (1975) (46)
Carboplatin for the Treatment of Children with Newly Diagnosed Optic Chiasm Gliomas: A Phase II Study (1999) (45)
High‐Dose Methotrexate in Acute Lymphoblastic Leukemia: Where Is the Evidence for Its Continued Use? (2005) (43)
Ifosfamide: should the honeymoon be over? (1995) (42)
Back to the basics: the importance of concentration x time in oncology. (1993) (42)
Treatment of meningeal relapse in childhood acute lymphoblastic leukemia. I. Results of craniospinal irradiation. (1984) (42)
Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia. (2009) (41)
Steroid-induced alterations of mood and behavior in children during treatment for acute lymphoblastic leukemia (2005) (41)
Effects of Overexpression of γ-Glutamyl Hydrolase on Methotrexate Metabolism and Resistance (2001) (40)
Identification of two mutant alleles of transcobalamin II in an affected family. (1994) (39)
Intensive Alternating Drug Pairs After Remission Induction for Treatment of Infants With Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Pilot Study (1998) (38)
Plasma homocysteine levels and folate status in children with sickle cell anemia. (1999) (35)
Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor (1997) (34)
Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. (1998) (34)
Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro (2012) (34)
Phase I study of ICRF-187 in pediatric cancer patients and comparison of its pharmacokinetics in children and adults. (1986) (33)
The relative tolerance of children and adults to anticancer drugs. (1981) (32)
Folate Receptor-α (2002) (32)
High dose methotrexate therapy: insecure rationale? (1988) (32)
Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World? (2011) (32)
Methotrexate and folate content of erythrocytes in patients receiving oral vs intramuscular therapy with methotrexate. (1984) (30)
A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro. (1996) (29)
5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines. (1993) (28)
Analysis of methotrexate polyglutamate derivatives in vivo. (1986) (28)
Systemic Methotrexate Exposure Is Greater After Intrathecal Than After Oral Administration (2003) (28)
Hepatic ultrastructure in leukemic children treated with methotrexate and 6‐mercaptopurine (1983) (27)
Mortality in pediatric phase I clinical trials. (1989) (27)
Similarity of folate receptor expression in UMSCC 38 cells to squamous cell carcinoma differentiation markers. (1995) (26)
Pharmacodynamic properties of methotrexate and AminotrexateTM during weekly therapy (2006) (24)
Effect of [3H]methotrexate impurities on apparent transport of methotrexate by a sensitive and resistant L1210 cell line. (1980) (24)
Folate and methotrexate polyglutamate tissue levels in rhesus monkeys following chronic low-dose methotrexate. (1987) (24)
Osteosarcoma cells, resistant to methotrexate due to nucleoside and nucleobase salvage, are sensitive to nucleoside analogs (2002) (24)
Methotrexate, homocysteine, and seizures. (1998) (23)
Phase II Trial of Oral Aminopterin for Adults and Children with Refractory Acute Leukemia (2005) (23)
Use of a novel genetic mouse model to investigate the role of folate in colitis-associated colon cancer. (2009) (23)
Metronomic therapy from a pharmacologist's view. (2006) (22)
Separation and identification of subpicomole amounts of methotrexate polyglutamates in animal and human biopsy material. (1982) (22)
Methotrexate and childhood leukemia. (1991) (22)
Regulation of folate receptor internalization by protein kinase C alpha. (2009) (22)
Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B—lineage acute lymphoblastic leukemia. A pediatric oncology group pilot study (1995) (22)
Effects of folate and folylpolyglutamyl synthase modulation on chemosensitivity of breast cancer cells (2007) (22)
Effects of single-dose and fractionated cranial irradiation on rat brain accumulation of methotrexate. (1984) (22)
Receptor-mediated folate uptake is positively regulated by disruption of the actin cytoskeleton. (1998) (22)
Intensive alternating drug pairs for treatment of high‐risk childhood acute lymphoblastic leukemia. A pediatric oncology group pilot study (1993) (22)
Effects of overexpression of gamma-Glutamyl hydrolase on methotrexate metabolism and resistance. (2001) (21)
Identification of a point mutation in the folate receptor gene that confers a dominant negative phenotype. (1995) (21)
γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate (2013) (20)
Renal irradiation and the pharmacology and toxicity of methotrexate and cisplatinum. (1986) (20)
In situ methotrexate polyglutamate formation in rat tissues. (1983) (20)
Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. (1998) (19)
Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study. (1996) (19)
Carboplatin (CBDCA), iproplatin (CHIP), and high dose cisplatin in hypertonic saline evaluated for tubular nephrotoxicity (2004) (18)
Evidence for CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. (1989) (18)
Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. (1990) (17)
Ratio of methotrexate to folate uptake by lymphoblasts in children with B-lineage acute lymphoblastic leukemia: a pilot study. (2000) (15)
Phase I trial of mitoxantrone in children. (1985) (15)
Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia (2008) (15)
Phase I Trial and Pharmacokinetic Study of Raltitrexed in Children with Recurrent or Refractory Leukemia: A Pediatric Oncology Group Study (2005) (15)
Phase I trial of trimetrexate in pediatric solid tumors: a Pediatric Oncology Group study. (1993) (14)
Seven-week continuous-infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study. (1997) (14)
Pulmonary toxicity of deferoxamine in children with advanced cancer. (1991) (14)
A mechanism of resistance to methotrexate. NADPH but not NADH stimulation of methotrexate binding to dihydrofolate reductase. (1983) (14)
PMA alters folate receptor distribution in the plasma membrane and increases the rate of 5-methyltetrahydrofolate delivery in mature MA104 cells. (1998) (13)
Red blood cell methotrexate and folate levels in children with acute lymphoblastic leukemia undergoing therapy: a Pediatric Oncology Group pilot study (2004) (12)
Parameningeal alveolar rhabdomyosarcoma with an isolated pancreatic metastasis. (1999) (12)
Translocations involving chromosome 12p11-13, methotrexate metabolism, and outcome in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. (1998) (12)
Evidence for Negative Feedback of Extracellular Methotrexate on Blasts of Acute Lymphoblastic Leukemia in Vitro (1997) (12)
UMSCC38 cells amplified at 11q13 for the folate receptor synthesize a mutant nonfunctional folate receptor. (1994) (12)
The reticulocytic rat: a model for analysis of methotrexate polyglutamate dynamics in situ. (1984) (12)
Fractionated cyclophosphamide and etoposide for children with advanced or refractory solid tumors: a phase II window study. (2000) (11)
Metronomic therapy: it makes sense and is patient friendly. (2005) (11)
Pharmacodynamic properties of methotrexate and AminotrexateTM during weekly therapy (2006) (11)
Oral versus intravenous methotrexate: another opinion. (1998) (11)
Aziridinylbenzoquinone (AZQ) treatment of central nervous system leukemia. (1982) (11)
Phase I studies of continuous-infusion paclitaxel given with standard aggressive radiation therapy for locally advanced solid tumors. (1995) (10)
Antimetabolites: A new perspective (2005) (10)
Imaging of folate receptors with I-125 labeled folate using small animal imaging system built with plastic scintillating optical fibers (1994) (10)
Secondary acute myeloid leukemia in Hispanic children. (1993) (10)
Autism Speaks: meeting on folate metabolism and Autism spectrum disorders, March 19-20, 2009, Washington, DC. (2011) (9)
Potentiation of cisplatin ototoxicity by noise. (1990) (9)
A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors (2008) (9)
5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICA-riboside) as a targeting agent for therapy of patients with acute lymphoblastic leukemia: are we there and are there pitfalls? (2007) (9)
Seven-week continuous-infusion paclitaxel with concurrent radiotherapy for locally advanced head and neck squamous cell cancer: a phase I study. (1997) (9)
High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: why and how? (2004) (8)
High-dose methotrexate: insecure rationale: take 2. (2008) (8)
The bullseye of cancer therapy: a moving target. (2003) (8)
Methotrexate content in squamous cell carcinoma of the head and neck after low-dose methotrexate. (1994) (8)
Looking at the seemingly contradictory role of vinblastine in anaplastic large-cell lymphoma from a metronomic perspective. (2011) (8)
Successful carboxypeptidase G2 rescue in delayed MTX-elimination due to renal failure. (1995) (7)
Phase II trial of ICRF-187 in children with solid tumors and acute leukemia (1991) (7)
High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection? (1998) (7)
A call to action: Cancer in adolescents and young adults: An unrecognized healthcare disparity. (2006) (6)
Folate, antifolates, and folate analogs in Pediatric Oncology (2004) (6)
Can targeted therapy be successful without metronomic scheduling? (2012) (6)
Methotrexate Polyglutamation May Lack Prognostic Significance in Children With B-Cell Precursor Acute Lymphoblastic Leukemia Treated With Intensive Oral Methotrexate (2002) (6)
Folate receptor imaging with 125I labeled folic acid with a whole body small animal imaging device built with plastic scintillating optical fibers (1995) (6)
High-dose methotrexate: is it warranted? (1994) (6)
Delayed methotrexate clearance in a patient with sickle cell anemia and osteosarcoma. (1999) (5)
Role of Methotrexate in the Treatment of Acute Lymphoblastic Leukemia (2003) (5)
Treatment of refractory acute lymphoblastic leukemia with teniposide and cytarabine. (1986) (5)
Folate Receptors and Therapeutic Applications (2011) (5)
Vitamin receptors: Folate binding proteins (1994) (5)
Cancer pain, suffering, and spirituality: a Middle Eastern Cancer Consortium meeting. (2010) (4)
A phase I study of nifurtimox in patients with relapsed/refractory neuroblastoma (2008) (4)
Folate receptor-α - an update. (2002) (4)
Folate and anti-folate transport in mammalian cells. (1980) (4)
Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors (1990) (4)
HIGH-DOSE METHOTREXATE IS LETHAL TO RATS. WHY GIVE IT TO CHILDREN? (2000) (4)
Methotrexate (MTX) concentration in tumors following low-dose MTX (1987) (4)
"Beriberi" interesting! (2003) (4)
Purification of folate binding factors. (1980) (3)
L'asparaginase and methotrexate combinations: clashes of empiric success and laboratory models? (2007) (3)
Elevation of Homocysteine and Excitatory Amino Acid Neurotransmitters in the Cerebrospinal Fluid of Children Receiving Methotrexate for Leukemia • 671 (1997) (3)
Clinical aspects of pharmacogenetics of pain and co-morbidities of emotional distress. (2010) (3)
Middle East Cancer Consortium (MECC) Flying High but Under the Radar (2007) (3)
Aminopterin Can Replace Methotrexate for Children with Newly Diagnosed Acute Lymphoblastic Leukemia without Excessive Toxicity. (2004) (3)
High-performance liquid chromatography separation of aminopterin-polyglutamates within red blood cells of children treated for acute lymphoblastic leukemia. (2007) (3)
Serendipity-methotrexate and 6-mercaptopurine for continuation therapy for patients with acute lymphoblastic leukemia: the leukemic stem cell and beyond? (2009) (3)
A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia (2004) (3)
Folate and antifolate cell binding and accumulation at physiologic folate concentrations. (1987) (2)
The use of methotrexate in the treatment of childhood malignancies (2000) (2)
Why more 6-mercaptopurine? (1991) (2)
CALLA and protein kinase CK2 revisited: targetable molecules for treating patients with leukemia? (2010) (2)
What I did on my summer vacation! (2011) (2)
Methotrexate, folate and the brain. (1986) (2)
In Reply: Folate and Coated Charcoal Reagent (1976) (2)
Pediatric oncology group phase II trial of amsacrine in children with solid tumors. (1985) (2)
Megadose methylprednisolone therapy: 2 decades of experience and empiric success in need of explanation, validation, and exploitation. (2007) (2)
Annular air-curtain domes for sports stadia (1986) (2)
On maintaining the honor and sanctity of our profession: reflections and personal trials and a book review: sustaining the dignity and nobility of medical care. (2008) (1)
PAIN: Above All, Do No Harm, or Make Sure the Result is Worthy of the Suffering (2000) (1)
Are we getting closer to using methotrexate in an optimal manner? (2011) (1)
L-asparaginase: old dog, more tricks and leukemia: not simply a liquid tumor. (2005) (1)
382 DECREASED FOLATE ASSOCIATED WITH METHOTREXATE POLY GLUTAMATE ACCUMULATION IN CHRONICALLY TREATED MONKEYS (1985) (1)
Methotrexate metabolism. (1983) (1)
"Above all do no harm:" horizons in pediatric oncology. (1994) (1)
Low-dose methotrexate therapy for hepatoblastoma (2004) (1)
Phase I study of iproplatin in pediatric patients: a Pediatric Oncology Group Study. (1987) (1)
Marker turned target? A case to review neprilysin in ALL (or lessons learned at the American Association for Cancer Research Meetings, 2006). (2006) (1)
Effect of chronic methotrexate (MTX) treatment on tissue levels of folate and MTX polyglutamates (MTXGLU(n)) (1985) (1)
Fosfomycin--friend or foe? (1991) (1)
Don't throw out the baby with the bathwater! (2005) (1)
What is the price of an erythrocyte and neutrophil? (2004) (1)
Changing of the Guard (2004) (1)
Improved tolerance of children to anticancer drugs (1981) (1)
Caveolae : Where incoming and outgoing messengers meet (2005) (1)
A tribute to and celebration of life. (2004) (1)
O4-benzylfolic acid inactivates O6-alkylguanine-DNA alkyltransferase in brain tumor cell lines (2007) (1)
Concurrent intensive radiotherapy and prolonged continuous-infusion paclitaxel for locally advanced solid tumors: Results of three phase I trials (1997) (1)
Experimental investigation of annular air curtain domes (1985) (1)
Welcome to the New Year (2008) (1)
Acute lymphoblastic leukemia complicated by choroid plexus carcinoma. (1999) (1)
Abstract 1607: Effect of folate and GGH modulation on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate (2010) (0)
Phase II trial of mitoguazone in children with leukemia and lymphoma: a Pediatric Oncology Group Study. (1986) (0)
What is learned from an acronym? Convergence of treatments and/or diseases? (2007) (0)
"The odds are all or none!" An account of one family's Odyssey more than a half century ago. (2008) (0)
Prologue to Ignorance is the Greatest Risk. (2005) (0)
The solutions for one generation may become the problems of the next. (2004) (0)
Acknowledgement to reviewers 2009 (2009) (0)
Safety of low dose oral methotrexate and irradiation for treatment-of children with brain tumors (1994) (0)
Phase IIB Trial of Aminopterin in Multiagent Therapy for Children with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) at High Risk of Relapse. (2006) (0)
Abstract 3942: A pilot trial testing the feasibility of using molecular-guided therapy in patients with refractory or recurrent neuroblastoma (2011) (0)
Resistance to Antifolates (2003) (0)
A Tribute and Salute to an Outstanding Colleague. (2009) (0)
Letter tO the Editor (1989) (0)
Food for thought: homage to a versatile vitamin: lessons learned from nature and your mother "eat your spinach!". (2005) (0)
Strategies to Overcome Resistance to MTX Using New (or Older) AntiFols (2003) (0)
A Call to Dialog (2006) (0)
Organization of the methotrexate resistant mouse L5178YR dihydrofolate reductase gene and transformation of human HCT-8 cells by this gene. (1981) (0)
Abstract #LB-263: Elevated levels of circulating folate receptor alpha in women with ovarian cancer. (2009) (0)
Pharmacokinetics of MTX (2003) (0)
Reviewers of the Journal of Chemotherapy (2010) (0)
Abstract 992: Regulation of ABCG2 lysosomal degradation by xanthines: Role of the PI3K/AKT pathway. (2013) (0)
''TO THE HEART OF THE MATTER.'' (2000) (0)
Abstract 1596: Effects of folylpolyglutamyl synthase and γ-glutamyl hydrolase modulation on DNA methylation (2010) (0)
Abstract 5412: Nuclear AMPKα2 is a repressor of alternative splicing of a subset of cancer-associated genes. (2013) (0)
Aminopterin, Methotrexate, Trimethoprim, and Folic Acid (2002) (0)
Farletuzumab, a monoclonal antibody against folate receptor alpha (FRα), does not block folate or anti-folate binding or alter drug potency assessed in vitro. (2011) (0)
Abstract 2591: Folate receptor alpha: A promoter of cancer cell proliferation that is independent of folate (2011) (0)
Inadvertent Drug Interactions with MTX (2003) (0)
Upcoming Additions and Transitions (2009) (0)
IFOSFAMIDE : SHOULD THE HONEYMOON BE OVER ? : A TWO-DIMENSIONAL QUESTIONFOR A THREE-DIMENSIONAL PROBLEM. AUTHORS' REPLY (1995) (0)
Letter to the editor (1983) (0)
BINDING ASSAY FOR METHOTREXATE (2017) (0)
Losses, Transitions, Reflections and Motivations Through Mortality in 2010 (2010) (0)
Phase II Trial of Oral Aminopterin forAdults and Children with RefractoryAcute Leukemia (2005) (0)
Hepatoma-derived growth factor is a tumor-derived mesenchymal stem cell chemoattractant (2007) (0)
Liposomal anthracyclines for brain tumors. (1999) (0)
Setting priorities. (2012) (0)
In the future: when is a rose is a rose is a rose? (2005) (0)
The use of aminopterin for the treatment of acute lymphoblastic leukemia (2005) (0)
Abstract 1680: Effect of folate and γ-glutamyl hydrolase modulation on in vitro chemosensitivity of colon and breast cancer cells to antifolates and 5-fluorouracil (2011) (0)
The Myth of Pain. Valerie Gray Hardcastle (2001) (0)
Advances in Brief Receptor-mediated Folate Uptake Is Positively Regulated by Disruption of the Actin Cytoskeleton 1 (2006) (0)
Abstract 1668: Effect of folate and γ-glutamyl hydrolase modulation on in vivo chemosensitivity of colon cancer cells to 5-fluorouracil (2011) (0)
The 3 ts of therapy: typing, tailoring, and targeting. (2008) (0)
Childhood acute leukemia as a prototype of curable cancer. (1988) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Barton A. Kamen?

Barton A. Kamen is affiliated with the following schools:

Barton A. Kamen's Academic­Influence.com Rankings

Why Is Barton A. Kamen Influential?

Barton A. Kamen's Published Works

Published Works

What Schools Are Affiliated With Barton A. Kamen?

Barton A. Kamen's AcademicInfluence.com Rankings